Immunomodulatory therapy for melanoma: Ipilimumab and beyond Journal Article
| Authors: | Callahan, M. K.; Postow, M. A.; Wolchok, J. D. |
| Article Title: | Immunomodulatory therapy for melanoma: Ipilimumab and beyond |
| Abstract: | In 2011, the U.S. Food and Drug Administration approved the first new therapy for melanoma in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on activated T cells. Blockade of this important immune checkpoint can lead to durable tumor regression, and phase III studies show an overall survival benefit for patients with advanced melanoma. During the clinical development of ipilimumab, several unique features of this immunotherapy were identified, including the remarkable durability of responses and a distinct side-effects profile. We review the preclinical and clinical development of CTLA-4-blocking antibodies and describe current practices using ipilimumab for the treatment of advanced melanoma. Unique clinical issues related to ipilimumab will be summarized. Lastly, we will briefly preview combination therapies that incorporate ipilimumab and new checkpoint-targeting antibodies currently in clinical development. © 2013 Elsevier Inc. |
| Keywords: | cancer survival; unclassified drug; gene mutation; overall survival; drug activity; hepatitis; placebo; cancer combination chemotherapy; dose response; drug dose comparison; nonhuman; skin manifestation; adjuvant therapy; biological marker; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; glycoprotein gp 100; interleukin 2; ipilimumab; ticilimumab; cancer immunotherapy; lung non small cell cancer; neuropathy; steroid; drug screening; kidney carcinoma; immunoregulation; drug dose escalation; pneumonia; pruritus; rash; immune response; arthritis; pancreatitis; single drug dose; tumor immunity; colitis; dna vaccine; emollient agent; dermatitis; drug half life; peptide vaccine; cytotoxic t lymphocyte antigen 4; tumor vaccine; b raf kinase; cytopenia; t lymphocyte activation; repeated drug dose; skin surgery; antihistaminic agent; braf gene; enterocolitis; uveitis; myopathy; central nervous system metastasis; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); recombinant alpha2b interferon; phase 1 clinical trial (topic); hypophysitis; thyroiditis; mdx 1105; infliximab; melanoma skin cancer; nivolumab; amp 224; bms 936559; mk 3475; mpdl 3280a; mpdl 3281a; pidilizumab; rg 7446; rna vaccine |
| Journal Title: | Clinics in Dermatology |
| Volume: | 31 |
| Issue: | 2 |
| ISSN: | 0738-081X |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-01-01 |
| Start Page: | 191 |
| End Page: | 199 |
| Language: | English |
| DOI: | 10.1016/j.clindermatol.2012.08.006 |
| PROVIDER: | scopus |
| PMCID: | PMC3653249 |
| PUBMED: | 23438382 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 April 2013" - "CODEN: CLDEE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work